PATRICK J KERINS
CIK 1235112 · last filed 2025-03-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$23.05B
Companies
37
Total Filings
137
Lifetime Open-Market Net
$40.37M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BZFDW | Director | 3,791,905 | $0.02 | $89.1K | -$938.8K | 13 | 2025-03-14 |
| SGMT | 10%+ Owner | 3,013,414 | $7.27 | $21.91M | $0 | 1 | 2024-01-31 |
| PhaseBio Pharmaceuticals Inc (PHAS) Delisted | 10%+ Owner | 4,857,525 | $0.07 | $340.5K | -$1.57M | 1 | 2022-10-26 |
| COUR | 10%+ Owner | 13,732,280 | $5.85 | $80.33M | $0 | 2 | 2021-05-21 |
| SPT | 10%+ Owner | 38,644 | $8.69 | $335.8K | $0 | 1 | 2020-11-17 |
| NET | 10%+ Owner | 4,244,177 | $264.10 | $1.12B | -$15.05M | 5 | 2020-11-13 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | 10%+ Owner | 129 | $29.08 | $3.8K | $15.00M | 3 | 2020-09-16 |
| ARDX | 10%+ Owner | 8,097,725 | $5.08 | $41.18M | $31.67M | 7 | 2020-06-12 |
| TESARO, Inc. (TSRO) Delisted | 10%+ Owner | 0 | — | — | $46.68M | 6 | 2019-01-22 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 9,625,307 | — | — | $84.39M | 2 | 2018-12-14 |
| ASND | 10%+ Owner | 82,978,668 | $254.44 | $21.11B | $29.01M | 4 | 2018-09-10 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,312,877 | $1.07 | $3.54M | $2.00M | 1 | 2018-04-23 |
| APPN | 10%+ Owner | 14,635 | $27.35 | $400.3K | -$66.07M | 4 | 2018-02-15 |
| SYNLOGIC, INC. (SYBX) Delisted | 10%+ Owner | 281,929 | $0.69 | $194.5K | $0 | 2 | 2018-01-26 |
| Care.com Inc (CRCM) Delisted | 10%+ Owner | 2,256,517 | — | — | $0 | 2 | 2017-11-08 |
| RYTM | 10%+ Owner | 4,359,956 | $108.04 | $471.05M | $9.35M | 1 | 2017-10-10 |
| MULESOFT, INC (MULE) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2017-03-22 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 321,681 | — | — | $4.60M | 3 | 2016-09-30 |
| Zosano Pharma Corp (ZSAN) Delisted | 10%+ Owner | 2,943 | $0.56 | $1.6K | -$59.2K | 1 | 2016-09-15 |
| OPOWER, INC. (OPWR) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2016-06-14 |
| CHANNELADVISOR CORP (ECOM) Delisted | Director | 35,853 | $23.09 | $827.8K | -$43.15M | 16 | 2016-03-01 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 407,151 | $1.47 | $598.5K | $24.00M | 4 | 2016-01-12 |
| Millennial Media Inc. (MM) Delisted | Director | 15,625 | — | — | -$21.48M | 6 | 2015-10-23 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | 10%+ Owner | 594,245 | — | — | $0 | 1 | 2015-10-20 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 2,114,375 | — | — | $6.00M | 1 | 2015-10-06 |
| BOX | 10%+ Owner | 0 | $31.50 | $0 | $0 | 1 | 2015-01-29 |
| CVENT INC (CVT) Delisted | 10%+ Owner | 3,995,115 | $8.52 | $34.04M | -$46.24M | 5 | 2014-11-28 |
| DERM | 10%+ Owner | 3,502,922 | $6.31 | $22.10M | $1.11M | 1 | 2014-10-08 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | 1,376,495 | $18.62 | $25.63M | -$283.8K | 4 | 2014-08-29 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 1,789,420 | — | — | $3.00M | 1 | 2014-08-06 |
| GRPN | 10%+ Owner | 10,397 | $28.10 | $292.2K | $0 | 2 | 2013-09-17 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 11,974 | $0.08 | $972 | $17.11M | 2 | 2013-06-05 |
| WDAY | 10%+ Owner | 1,730 | $159.69 | $276.3K | $0 | 2 | 2013-04-11 |
| FUSION-IO, INC. (FIO) Delisted | 10%+ Owner | 3,751 | — | — | -$43.38M | 14 | 2012-09-06 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | 10%+ Owner | 1,590,142 | — | — | $5.00M | 1 | 2012-08-02 |
| ECHO | 10%+ Owner | 2,020,316 | $85.93 | $173.61M | $0 | 1 | 2012-03-01 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | 10%+ Owner | 0 | — | — | -$326.3K | 1 | 2011-03-14 |
Recent Filings · Page 4 of 14
137 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-08-01 | — | Mixed | +2,473,750 | $6.00M | |
| 2018-05-30 | ARDX | Grant (A) | +416,667 | $1.67M | EDGAR |
| 2018-05-09 | — | Mixed | — | $0 | |
| 2018-04-23 | Surface Oncology, Inc. (SURF) Delisted | Mixed | +3,312,877 | $2.00M | EDGAR |
| 2018-03-28 | ASND | Buy (P) | +6,571,164 | $12.59M | EDGAR |
| 2018-03-27 | — | Buy (P) | +2,123,892 | $5.73M | |
| 2018-03-23 | ASND | Buy (P) | +1,268,508 | $2.42M | EDGAR |
| 2018-03-06 | TESARO, Inc. (TSRO) Delisted | Buy (P) | +116,445 | $6.68M | EDGAR |
| 2018-02-15 | APPN | Mixed | +1,523 | $0 | EDGAR |
| 2018-01-26 | SYNLOGIC, INC. (SYBX) Delisted | Grant (A) | +410,000 | $4.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.